Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.52 |
| ▸ | CD38 | P28907 | 4/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405326 | 0.93 | CRHR1 (0.45) | CRHR1CD38 | |
| SCHEMBL5250243 | 0.92 | CRHR1 (0.53) | CRHR1CD38 | |
| SCHEMBL5249524 | 0.87 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5248198 | 0.87 | CRHR1 (0.49) | CRHR1CD38 | |
| SCHEMBL5248032 | 0.86 | CRHR1 (0.53) | CRHR1CD38PIK3R2 | |
| SCHEMBL5250092 | 0.84 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL5250132 | 0.84 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5250521 | 0.83 | CRHR1 (0.53) | CRHR1CD38 | |
| SCHEMBL5250398 | 0.81 | CD38 (0.41) | CD38PIK3R2 | |
| SCHEMBL5250170 | 0.80 | CRHR1 (0.54) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210207199-A1 | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | HMNC Holding GmbH (DE) | 2021-07-08 | — | — | US | disclosed |
| US-10837062-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-11-17 | — | — | US | disclosed |
| US-20190194752-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-06-27 | — | — | US | disclosed |
| US-10190168-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20150278438-A1 | GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150278438-A1 | GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | HMNC VALUE GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | HMNC VALUE GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| EP-1299378-B1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-7160900-B2 | Tetrahydropyridino or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-6852732-B2 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1299378-A4 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1299378-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | Taisho Pharmaceutical Co. Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002002549-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194752-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | AVPR1B, CRHR1, CRHR2 | CRHR1 2/4885CD38 3757/4885PIK3R2 4167/4885 |
| US-20150278438-A1 | GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | CRHR1, CRHR2, CRH | CRHR1 1/4885CD38 2785/4885PIK3R2 2703/4885 |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | CRH, CRHR1, CRHR2 | CRHR1 2/4885CD38 1069/4885PIK3R2 4525/4885 |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | AVPR1B, CRHR1, AVPR1A | CRHR1 2/4885CD38 1625/4885PIK3R2 3366/4885 |
| US-10190168-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | AVPR1B, CRHR1, AVPR1A | CRHR1 2/4885CD38 1625/4885PIK3R2 3366/4885 |
| US-10837062-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | AVPR1B, CRHR1, CRHR2 | CRHR1 2/4885CD38 3757/4885PIK3R2 4167/4885 |
| US-20210207199-A1 | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885CD38 610/4885PIK3R2 2737/4885 |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | CRHR1, CRHR2, VIPR1 | CRHR1 1/4885CD38 1069/4885PIK3R2 2539/4885 |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | CRHR1, CRHR2, AGTR1 | CRHR1 1/4885CD38 866/4885PIK3R2 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.